Premium
Phase I‐II study of aclarubicin for treatment of acute myeloid leukaemia
Author(s) -
Machover David,
Gastiaburu Julio,
Delgado Michel,
Goldschmidt Emma,
Benavides Manuel,
Misset JeanLouis,
Vassal Francoise,
Tapiero Haim,
Ribaud Patricia,
Schwarzenberg Léon,
Mathe Georges,
Hulhoven Reginal,
Lotz JeanPierre
Publication year - 1987
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1987.tb00020.x
Subject(s) - aclarubicin , medicine , myeloid leukaemia , refractory (planetary science) , incidence (geometry) , chemotherapy , myeloid leukemia , myeloid , gastroenterology , oncology , cytarabine , physics , optics , astrobiology
SUMMARY Aclarubicin (ACM) was administered as induction treatment to 38 evaluable patients with acute myeloid leukaemia (AML) who were either refractory to initial chemotherapy or in relapse. Thirteen patients received daily doses of ACM while the remaining 25 were given 10‐day courses with 10‐day intervals between courses. The overall CR rate was 34% and the incidence and severity of the toxic effects were related to the dose of ACM administered per course of therapy. Our results indicate that ACM is a major new drug for the treatment of AML.